Skip to main content

previous disabled Page of 2
and
  1. Article

    Open Access

    Study protocol for a pragmatic randomised controlled trial of comparing enhanced acceptance and commitment therapy plus (+) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors’ Rehabilitation Evaluation after CANcer (SURECAN) trial

    Two million people in the UK are living with or beyond cancer and a third of them report poor quality of life (QoL) due to problems such as fatigue, fear of cancer recurrence, and concerns about returning to w...

    Imran Khan, Stephanie J. C. Taylor, Clare Robinson, Elisavet Moschopoulou in Trials (2024)

  2. Article

    Open Access

    A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

    Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in pati...

    Thomas Starkey, Maria C. Ionescu, Michael Tilby, Martin Little in Scientific Reports (2023)

  3. Article

    Open Access

    Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

    Breast cancer metastasis accounts for most of the deaths from breast cancer. Identification of germline variants associated with survival in aggressive types of breast cancer may inform understanding of breast...

    Maria Escala-Garcia, Sander Canisius, Renske Keeman, Jonathan Beesley in Scientific Reports (2021)

  4. Article

    Open Access

    Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

    Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breas...

    Anna Morra, Maria Escala-Garcia, Jonathan Beesley, Renske Keeman in Breast Cancer Research (2021)

  5. Article

    Open Access

    Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA

    Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney in Nature Communications (2021)

  6. Article

    Open Access

    Genomic profile of advanced breast cancer in circulating tumour DNA

    The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma cir...

    Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney in Nature Communications (2021)

  7. Article

    Open Access

    The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review

    Cardiac autonomic neuropathy (CAN) is independently associated with silent myocardial ischaemia, major cardiovascular events, myocardial dysfunction and cardiovascular mortality. Several studies have highlight...

    Aikaterini Eleftheriadou, Scott Williams, Sarah Nevitt, Emily Brown in Diabetologia (2021)

  8. No Access

    Article

    Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy

    Cardiotoxicity can occur acutely during breast cancer treatment and impact the potential for the intended cancer treatment regime to be completed, or as a late effect affecting cancer survivorship. Indeed, the...

    Daniel H. Chen, Sara Tyebally, Michael Malloupas in Current Cardiology Reports (2021)

  9. Article

    Open Access

    Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

    Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinica...

    Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms in Nature Communications (2020)

  10. Article

    Open Access

    Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years

    Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal breast cancer, and approximately 20% of screen-detected tumours are pure DCIS. Most risk factors for breast cancer have similar as...

    Christos Petridis, Iteeka Arora, Vandna Shah, Anargyros Megalios in Breast Cancer Research (2019)

  11. No Access

    Article

    Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience

    Palbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Programme previously allowed patients to receive it in 4th line. Howeve...

    Nicolò Matteo Luca Battisti, Belinda Kingston in Breast Cancer Research and Treatment (2019)

  12. Article

    Open Access

    Genome-wide association study of germline variants and breast cancer-specific mortality

    We examined the associations between germline variants and breast cancer mortality using a large meta-analysis of women of European ancestry.

    Maria Escala-Garcia, Qi Guo, Thilo Dörk, Sander Canisius in British Journal of Cancer (2019)

  13. No Access

    Article

    Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

    Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also ...

    Andrew Tutt, Holly Tovey, Maggie Chon U. Cheang, Sarah Kernaghan in Nature Medicine (2018)

  14. Article

    Open Access

    PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression

    Lobular carcinoma in situ (LCIS) is a non-invasive breast lesion that is typically found incidentally on biopsy and is often associated with invasive lobular carcinoma (ILC). LCIS is considered by some to be a ri...

    Vandna Shah, Salpie Nowinski, Dina Levi, Irek Shinomiya in Breast Cancer Research (2017)

  15. Article

    Open Access

    Genetic predisposition to ductal carcinoma in situ of the breast

    Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is often associated with invasive ductal carcinoma (IDC), and is considered to be a non-obligate precursor of IDC. It is not clear to wh...

    Christos Petridis, Mark N. Brook, Vandna Shah, Kelly Kohut in Breast Cancer Research (2016)

  16. No Access

    Article

    Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer

    Regulators of transition through mitosis such as SURVIVIN and Aurora kinase A (AURKA) have been previously implicated in the initiation of chromosomal instability (CIN), a driver of intratumour heterogeneity. ...

    Rebecca Roylance, David Endesfelder in Breast Cancer Research and Treatment (2014)

  17. Article

    Erratum: Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

    Nat. Genet. 45, 136–144 (2013); published online 23 December 2012; corrected after print 8 May 2013 In the version of this article initially published, the name of author Estrella Guarino was incorrectly liste...

    Claire Palles, Jean-Baptiste Cazier, Kimberley M Howarth, Enric Domingo in Nature Genetics (2013)

  18. No Access

    Article

    Taxane benefit in breast cancer—a role for grade and chromosomal stability

    In this Perspectives article, the authors propose that lower histological grade in breast cancer might be a hallmark of relative chromosomal stability, which in turn might be predictive of additional benefit f...

    Roger P. A'Hern, Mariam Jamal-Hanjani, A. Marcell Szász in Nature Reviews Clinical Oncology (2013)

  19. No Access

    Article

    Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

    Ian Tomlinson and colleagues report the identification of germline variants in POLE and POLD1 that are susceptibility alleles for colorectal cancer. POLE and POLD1 encode DNA polymerases that function in DNA repl...

    Claire Palles, Jean-Baptiste Cazier, Kimberley M Howarth, Enric Domingo in Nature Genetics (2013)

  20. No Access

    Protocol

    Fluorescence In Situ Hybridization and Comparative Genomic Hybridization

    This chapter discusses the complementary methodologies of fluorescence in situ hybridization and comparative genomic hybridization. Fluorescence in situ hybridization uses fluorescently labeled DNA probes (whole ...

    Patricia Gorman, Rebecca Roylance in Breast Cancer Research Protocols (2006)

previous disabled Page of 2